Development and application of PROVAX(TM) adjuvant formulation for subunit cancer vaccines

Advanced Drug Delivery Reviews

Volumn 32, Issue 3, 1998, Pages 187-197

  Hariharan, Kandasamy ^a   Hanna, Nabil ^a  

^a BIOGEN   (United States)

Author keywords

Adjuvant formulation; AF; Cancer vaccines; CTL vaccines; Provax(TM)

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; ONCOLOGY; TOXICITY; VACCINES;

CYTOTOXICITY;

CONTROLLED DRUG DELIVERY;

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; PLURONIC L 121; POLOXAMER; POLYSORBATE 80; PROVAX; QUIL A; RECOMBINANT VACCINE; ROBANE; SAF M; SPINACANE; SQUALENE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN PRESENTATION; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; EMULSION; HELPER CELL; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; TUMOR REGRESSION; VACCINE PRODUCTION;

EID: 0032490611     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00010-6     Document Type: Review

References (55)

1. J.L. Bussiere, G.C. McCormick and J.D. Green, Pre-clinical Safety Assessment Considerations in Vaccine Development, in: Vaccine Design: The Subunit and Adjuvant Approach, Plenum Press, New York, 1995, pp. 61-79.
2. Struck M.M. Vaccine R & D success rates and development times. Nature Biotechnol. 14:1996;591-593.
3. M.J. Newman, M.F. Powell, Immunological and Formulation Design Considerations for Sub-unit Vaccines, in: Vaccine Design: The Sub-unit and Adjuvant Approach. Plenum Press, New York, (1995) pp. 61-79.
4. Pardoll D.M. Cancer vaccines: a road map for the next decade. Curr. Opin. Immunol. 8:1996;619-621.
5. Baxevanis C.N., Papamichail M. Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy. Crit. Rev. Hematol. 16:1994;157-179.
6. B. Himmelweit (Ed.) The Collected Papers of Paul Ehrlich, Pergamon Press, Oxford, 1957.
7. Greenberg P.D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:1991;281-355.
8. Robbins P.F., Kawakami Y. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8:1996;628-636.
9. Rosenberg S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today. 18:1997;175-182.
10. Coulie P.G. Human tumor antigens recognized by T cells: new perspectives for anti-cancer vaccines? Mol. Med. Today. 3:1997;261-268.
11. Mukherji B., Chakraborty N.G. Immunobiology and immunotherapy of melanoma. Curr. Opin. Oncol. 7:1995;175-184.
12. Huber D., Philipp A., Fontana J. Protease inhibitors interfere with the transforming growth factor-β-dependent but not the transforming growth factor-β-independent pathway of tumor cell-mediated immunosuppression. J. Immunol. 148:1992;277-284.
13. Seliger B., Maeurer M.J., Ferrone S. TAP off-tumors on. Immunol. Today. 18:1997;292-298.
14. Matsuda M., Petersson M., Lenkei R., Taupin J.L., Magnusson I., Mellstedt H., Anderson P., Kiessling R. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with stage of the disease. Int. J. Cancer. 61:1995;765-772.
15. Hahne M., Rimoldi D., Schröter X., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J.-C., Tschopp J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1996;1363-1366.
16. Matsumura M., Fremont D.H.P., Peterson A., Wilson I.A. Emerging principles for the recognition of peptide antigens by MHC Class I molecules. Science (Washington, DC). 257:1992;927-934.
17. Long E.O. Intracellular traffic and antigen processing. Immunol. Today. 10:1989;232-234.
18. Townsend A., Ohlen C., Bastin J., Ljunggren H.-G., Foster L., Kärre K. Association of Class I major histocompatibililty heavy and light chains induced by viral peptides. Nature (London). 340:1989;443-448.
19. Pardoll D.M. Cancer Vaccines. Immunol. Today. 14:1993;310-316.
20. Melief C.J.M., Kast W.M. T-cell immunotherapy of cancer. Res. Immunol. 142:1991;425-429.
21. Disis M.L., Cheever M.A. Oncogenic proteins as tumor antigens. Curr. Opin. Immunol. 8:1996;637-642.
22. Hadden J.W. Immunostimulants. Immunol. Today. 14:1993;275-280.
23. G. Forni, F. Pericle, M. Giovarelli, In: A. Gearing, J. Rossio, J.J. Oppenheim (Eds.), Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis and Therapy, Oxford University Press, London, 1993, pp. 187-194.
24. Pardoll D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:1995;399-415.
25. Musiani P., Modesti A., Giovarelli M., Cavallo F., Colombo M.P.P., Lollini L., Forni G. Cytokines, tumor-cell death and immunogenicity: a question of choice. Immunol. Today. 18:1997;32-36.
26. Liu B., Podack E.R.J., Allison P., Malek T.R. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J. Immunol. 156:1996;1117-1125.
27. Kwong Y.T., Zsremba A., Nieroda M., Zhu Z.J., Hamilton M., Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA Vaccine. J. Natl. Cancer Inst. 87:1995;982-990.
28. R.W. Chestnut, A. Sette, E. Celis, P. Wentworth, R.T. Kubo, J. Alexander, G. Ishioka, A. Vitiello, H.M. Grey, Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer, in: Vaccine Design: The Sub-unit and Adjuvant Approach, Plenum Press, New York, 1995, pp. 847-874.
29. Talarico D., Ittmann M., Belsari A., Deli-Bori P., Basch R.S., Basilico C. Protection of mice against tumor growth by immunization with an oncogene-encoded growth factor. Proc. Natl. Acad. Sci. USA. 87:1990;4222-4225.
30. Restifo N.P. The new vaccines: building viruses that elicit anti-tumor immunity. Curr. Opin. Immunol. 8:1996;658-663.
31. Aldovini A., Young R.A. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature (London). 351:1991;479-482.
32. Paterson Y., Ikonomidis G. Recombinant Listeria monocytogenes cancer vaccines. Curr. Opin. Immunol. 8:1996;664-669.
33. Ulmer J.B., Donnelly J.J., Parker S.E.et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
34. Deres K., Schild H., Wiesmüller K.H., Lang G., Rammensee H.G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature (London). 342:1989;561-564.
35. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMS. Nature (London). 344:1990;873-875.
36. Raychaudhuri S., Tonks M., Carbone F.R., Ryskamp T., Morrow W.J.W., Hanna N. Induction of antigen-specific Class I-restricted cytotoxic cells by soluble proteins in vivo. Proc. Natl. Acad. Sci. USA. 89:1992;8308-8312.
37. Hariharan K., Braslawsky G., Black A., Raychaudhuri S., Hanna N. The induction of cytotoxic T cells and tumor regression by soluble antigen formulation. Cancer Res. 55:1995;3486-3489.
38. Moore M.W.F., Carbone R., Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 54:1988;777-785.
39. Allison A.C., Byars N.E. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods. 95:1986;157-168.
40. D.M. Lidgate, N.E. Byars, Development of an emulsion-based muramyl dipeptide adjuvant formulation for vaccines, in: Vaccine Design: The Subunit and Adjuvant Approach, Plenum Press, New York, 1995, pp. 313-324.
41. F.R. Vogel, M.F. Powell, A compendium of vaccine adjuvants and excipients, in: Vaccine Design: The Subunit and Adjuvant Approach, Plenum Press, New York, 1995, pp. 141-227.
42. Fenton R.G.C., Keller J., Hanna N., Taub D.D. Induction of T-cell immunity against ras oncoproteins by soluble protein or ras-expressing Escherichia coli. J. Natl. Cancer Inst. 87:1995;1853-1861.
43. K. Hariharan, G. Braslawsky, G. Barnett, R.S. Berquist, T. Huynh, N. Hanna, A. Black, Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in adjuvant formulation PROVAX™. Int. J. Oncol. 12 (1998) in press.
44. Livingston P.O., Wong Y.C., Adluri S., Tao Y., Padavan M., Parente R., Hanlon C., Jones-Calves M., Helling F., Ritter G., Oettgen H.F., Old L.J. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccine with GM2 ganglioside. J. Clin. Oncol. 12:1994;1036-1044.
45. Peet N.M., McKeating J.A., Ramos B., Klonisch T., De Souza J.B., Delves P.J., Lund T. Comparison of nucleic acid and protein immunization for the induction of antibodies specific for HIV-gp120. Clin. Exp. Immunol. 109:1997;226-232.
46. Souberbielle B.E., Knight B.C., Morrow W.J.W., Darling D., Fraziano M., Marriott J.B., Cookson S., Farzaneh F., Dalgleish A.G. Comparison of IL-2 and IL-4 transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine. Gene Ther. 3:1996;853-858.
47. Kovacsovics-Bankowski M., Rock K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC Class I molecules. Science. 267:1995;243-245.
48. + cytotoxic T-cell responses? A paradox revisited. Immunol. Today. 1:1993;344-348.
49. Xue B.-H., Zhang Y., Sosman J.A., Peace D.J. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate. 30:1997;73-78.
50. Israeli R.S.C., Powell T.J., Corr G.W., Fair R., Heston W.D.W. Expression of the prostate-specific membrane antigen. Cancer Res. 54:1994;1807-1811.
51. Sahin U., Tureci O., Schmitt H.et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA. 92:1995;11810-11813.
52. Becker J.C., Varki N., Gillies S.D., Furakawa K., Reisfeld R.A. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. USA. 93:1996;7826-7831.
53. Deo Y.M., Graziano R.F., Repp R., van de Winkel J.G.J. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol. Today. 18:1997;127-135.
54. Maraskovsky E.et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1996;1953-1962.
55. van Schooten W.C.A., Strang G., Palathumpat V. Biological properties of dendritic cells: implications to their use in the treatment of cancer. Mol. Med. Today. 3:1997;254-260.